RENNIE PEPPERMINT

Country: Israel

Language: English

Source: Ministry of Health

Active ingredient:

CALCIUM CARBONATE; MAGNESIUM CARBONATE

Available from:

BAYER ISRAEL LTD

ATC code:

N/A

Pharmaceutical form:

CHEWABLE TABLETS

Composition:

CALCIUM CARBONATE 680 MG; MAGNESIUM CARBONATE 80 MG

Administration route:

PER OS

Prescription type:

Not required

Manufactured by:

DELPHARM GAILLARD, FRANCE

Therapeutic indications:

Relief of hyperacidity and heartburn.

Authorization date:

2016-11-30

Patient Information leaflet

PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS
(PREPARATIONS) - 1986
This medicine is dispensed without a doctor's prescription
RENNIE
® PEPPERMINT
CHEWABLE TABLETS
ACTIVE INGREDIENTS:
Every chewable tablet contains:
Calcium carbonate 680 mg (equivalent to 272 mg calcium)
Magnesium carbonate (heavy) 80 mg
INACTIVE INGREDIENTS AND ALLERGENS: see section 2 under "Important
information about some of
this medicine’s ingredients" and section 6 "Additional information".
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet contains
concise information about this medicine. If you have any further
questions, consult your doctor or
pharmacist.
Take the medicine according to the instructions in the section about
dose in this leaflet. Consult
your pharmacist if you need further information. Contact a doctor if
your symptoms of illness get
worse or do not improve after 14 days.
1.
WHAT IS THE MEDICINE INTENDED FOR?
This medicine is intended for the relief of gastric hyperacidity and
heartburn.
THERAPEUTIC GROUP: antacid.
Rennie is used for treatment of symptoms resulting from reflux of
acidic gastric content to the
oesophagus and mouth, causing a sensation of burning or pain behind
the sternum.
Rennie is also used for treatment of symptoms caused by hyperacidity
of gastric content, e.g. in
case of heartburn. Rennie can also be used for the treatment of
symptoms caused by an ulcer in
the upper digestive tract.
2.
BEFORE USING THE MEDICINE
DO NOT USE THE MEDICINE IF:
•
you are sensitive (allergic) to calcium carbonate or to magnesium
carbonate or to any of the
additional ingredients contained in the medicine (for the list of the
inactive ingredients, see
section 6
"Additional information").
•
you suffer from a severe kidney dysfunction or kidney stones.
•
you suffer from high calcium levels or low phosphate levels in the
blood.
SPECIAL WARNINGS ABOUT USING THIS MEDICINE
BEFORE STARTING TREATMENT WITH THE MEDICINE, TELL YOUR DOCTOR IF:
•
you suffer from sarcoidosis (an

Summary of Product characteristics

1. NAME OF THE MEDICINAL PRODUCT
Rennie Peppermint
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each chewable tablet contains 680 mg calcium carbonate and 80 mg
magnesium carbonate.
Excipients with known effect: each chewable tablet contains 475 mg
sucrose.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Chewable tablets.
Rennie is a cream coloured, square tablet with rounded edges inscribed
with “RENNIE” on
both sides; the tablet smells of peppermint.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Relief of hyperacidity and heartburn.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
For adults and children over the age of 12 years:
1 -2 tablets are to be sucked or chewed, as needed, preferably circa 1
hour after food and
before going to bed.
For the treatment of heartburn, an additional 1 -2 tablets may be
taken between those
times.
Do not take more than 10 tablets per day. The patient must be advised
to consult a doctor
if the symptoms persist for longer than 14 days.
It is advisable to wait circa 1 -2 hours between taking other
medicines and taking Rennie.
Paediatric patients:
This medicine is not to be taken by children under the age of 12
years. The safety and
efficacy in children aged under 12 years have not yet been
established.
Method of administration
For oral use. To be chewed or sucked. The tablets can be taken without
water.
As with all antacids, in the event of persistent symptoms, diagnostic
measures are
recommended to exclude serious diseases.
For special warnings and precautions during use: see section 4.4.
4.3 CONTRAINDICATIONS
-
Hypersensitivity to the active substances or to any of the excipients
listed in
section 6.1.
-
Severe renal insufficiency, hypercalcaemia and/or conditions resulting
in
hypercalcaemia.
-
Pre-existing hypophosphataemia.
-
Nephrolithiasis due to calcium-containing stones.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Prolonged use should be avoided.
If symptoms persist or do not (fully) disappear, further medical
investigation is required.